A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2

Mao, Shanhong; Li, Shiyou; Zhang, Yuxin; Long, Luoxin; Peng, Junfeng; Cao, Yuanyan; Mao, Jessica Z; Xin, Qi; San, Guoliang; Ding, Jun; Jiang, Jun; Bai, Xin; Wang, Qianting; Xu, Ping; Xia, Huan; Lü, Ling; Xie, Liangzhi; Kong, Desheng; Zhu, Shuangli; Xu, Wenbo

doi:10.1016/j.nantod.2022.101730

Cited by 16 publications

(19 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…developed a needle‐free injection system to deliver a SARS‐CoV‐2 mRNA‐LNP vaccine, which could generate less pain and better immunogenicity than the traditional needle injection. [ 138 ]…”

Section: Lnp Developmentmentioning

confidence: 99%

“…Recently, Mao et al developed a needle-free injection system to deliver a SARS-CoV-2 mRNA-LNP vaccine, which could generate less pain and better immunogenicity than the traditional needle injection. [138] Nebulization provides great potential for lung-targeted therapy because it could distribute mRNA-LNPs directly into the lungs to maximize local mRNA concentration. Lokugamage et al optimized LNP formulations using a cluster-based screening method for nebulized mRNA delivery.…”

Section: Choice Of Administration Routesmentioning

confidence: 99%

See 1 more Smart Citation

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

et al. 2023

View full text Add to dashboard Cite

Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of COVID‐19 mRNA vaccines (Comirnaty and Spikevax). To meet the therapeutic purpose, it is required that mRNA must enter the target cells and express sufficient proteins. Therefore, the development of effective delivery systems is necessary and crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle that has indeed accelerated mRNA applications in humans, as several mRNA‐based therapies have already been approved or are in clinical trials. In this review, we focus on mRNA‐LNP mediated anticancer therapy. We summarize the main development strategies of mRNA‐LNP formulations, discuss representative therapeutic approaches in cancer, and point out current challenges and possible future directions of this research field. We hope these delivered messages could help further improve the application of mRNA‐LNP technology in cancer therapy.This article is protected by copyright. All rights reserved

show abstract

Section: Lnp Developmentmentioning

confidence: 99%

Section: Choice Of Administration Routesmentioning

confidence: 99%

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It ensures the lipids do not become too sticky during cold storage. Recently, Mao et al [ 74 ] reported the development of a needle-free injectable COVID-19 mRNA vaccine. This formulation utilizes sucrose as an antioxidant for LNP particles.…”

Section: Factors Affecting Mrna Vaccine Stabilitymentioning

confidence: 99%

Research Advances on the Stability of mRNA Vaccines

Cheng

Wang

Bai

et al. 2023

Viruses

View full text Add to dashboard Cite

Compared to other vaccines, the inherent properties of messenger RNA (mRNA) vaccines and their interaction with lipid nanoparticles make them considerably unstable throughout their life cycles, impacting their effectiveness and global accessibility. It is imperative to improve mRNA vaccine stability and investigate the factors influencing stability. Since mRNA structure, excipients, lipid nanoparticle (LNP) delivery systems, and manufacturing processes are the primary factors affecting mRNA vaccine stability, optimizing mRNA structure and screening excipients can effectively improve mRNA vaccine stability. Moreover, improving manufacturing processes could also prepare thermally stable mRNA vaccines with safety and efficacy. Here, we review the regulatory guidance associated with mRNA vaccine stability, summarize key factors affecting mRNA vaccine stability, and propose a possible research path to improve mRNA vaccine stability.

show abstract

“…Therefore, optimizing the design of LNPs to enable sequential delivery or simultaneous delivery of multiple components for human nucleic acid delivery is also essential. [88] Copyright 2023, American Chemical Society. b) Schematic illustration of LNP pulmonary inhalation nebulized delivery.…”

Section: Adding Other Ingredientsmentioning

confidence: 99%

Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid

Jia,

Wang,

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug delivery vehicles. LNPs prevent the degradation of cargo nucleic acids during blood circulation. Upon entry into the cell, specific components of the lipid nanoparticles can promote the endosomal escape of nucleic acids. These are the basic properties of lipid nanoparticles as nucleic acid carriers. As LNPs exhibit hepatic aggregation characteristics, enhancing targeting out of the liver is a crucial way to improve LNPs administrated in vivo. Meanwhile, endosomal escape of nucleic acids loaded in LNPs is often considered inadequate, and therefore, much effort is devoted to enhancing the intracellular release efficiency of nucleic acids. Here, we concluded different strategies to efficiently deliver nucleic acid delivery from LNPs and investigated their mechanisms. In addition, based on the information on LNPs that are in clinical trials or have completed clinical trials, we discussed the issues that are necessary to be approached in the clinical translation of LNPs, which we hope will shed light on the development of LNP nucleic acid drugs.This article is protected by copyright. All rights reserved

show abstract

A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2

Cited by 16 publications

References 58 publications

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Research Advances on the Stability of mRNA Vaccines

Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid

Contact Info

Product

Resources

About